

## Case Series Drug Analysis Print

**Name: Menjugate FOI 21/1063**

Report Run Date: 07-Oct-2021  
Data Lock Date: 30-Sep-2021 18:30:04  
Earliest Reaction Date: 08-Nov-1999  
MedDRA Version: MedDRA 24.0

Menjugate FOI  
21/1063:

All UK spontaneous reports received up until 30-Sep-2021 for the Menjugate vaccine analysis print. A report of a suspected ADR to the Yellow Card scheme does not necessarily mean that it was caused by the vaccine, only that the reporter has a suspicion it may have. Underlying or previously undiagnosed illness unrelated to vaccination can also be factors in such reports. The relative number and nature of reports should therefore not be used to compare the safety of the different vaccines. All reports are kept under continual review in order to identify possible new risks.

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Blood disorders</b>		
<i>Coagulopathies</i>		
Coagulopathy	1	0
<i>Lymphatic system disorders NEC</i>		
Lymphadenopathy	7	0
<i>Thrombocytopenias</i>		
Immune thrombocytopenia	2	0
Thrombocytopenia	1	0
<b>Blood disorders SOC TOTAL</b>	<b>11</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Cardiac disorders</b>		
<i>Cardiac disorders NEC</i>		
Cardiovascular disorder	2	0
<i>Cardiac signs and symptoms NEC</i>		
Palpitations	3	0
<i>Rate and rhythm disorders NEC</i>		
Arrhythmia	1	0
Bradycardia	12	0
Tachycardia	9	0
<b>Cardiac disorders SOC TOTAL</b>	<b>27</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Congenital disorders</b>		
<i>Cardiac septal defects congenital</i>		
Atrial septal defect	1	0
<b>Congenital disorders SOC TOTAL</b>	<b>1</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Ear disorders</b>		
<i>Ear disorders NEC</i>		
Ear pain	6	0
<i>Hearing losses</i>		
Deafness transitory	2	0
Hypoacusis	4	0
<i>Inner ear signs and symptoms</i>		
Tinnitus	11	0
Vertigo	2	0
<b>Ear disorders SOC TOTAL</b>	<b>25</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Eye disorders</b>		
<i><b>Glaucomas (excl congenital)</b></i>		
Glaucoma	1	0
<i><b>Lid, lash and lacrimal infections, irritations and inflammations</b></i>		
Swelling of eyelid	1	0
<i><b>Ocular disorders NEC</b></i>		
Eye disorder	1	0
Eye pain	11	0
Eye swelling	8	0
Periorbital oedema	2	0
<i><b>Ocular infections, inflammations and associated manifestations</b></i>		
Eye irritation	1	0
Eye pruritus	2	0
<i><b>Ocular nerve and muscle disorders</b></i>		
Eye movement disorder	13	0
<i><b>Ocular sensation disorders</b></i>		
Abnormal sensation in eye	1	0
Photophobia	20	0
<i><b>Pupil disorders</b></i>		
Mydriasis	5	0
Pupils unequal	2	0
<i><b>Visual disorders NEC</b></i>		
Diplopia	10	0
Photopsia	6	0
Vision blurred	46	0
<i><b>Visual impairment and blindness (excl colour blindness)</b></i>		
Blindness transient	4	0
Visual impairment	6	0
<b>Eye disorders SOC TOTAL</b>	<b>140</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Gastrointestinal disorders</b>		
<i>Diarrhoea (excl infective)</i>		
Diarrhoea	27	0
<i>Dyspeptic signs and symptoms</i>		
Dyspepsia	1	0
<i>Flatulence, bloating and distension</i>		
Abdominal distension	1	0
<i>Gastrointestinal and abdominal pains (excl oral and throat)</i>		
Abdominal pain	84	0
Abdominal pain upper	102	0
<i>Gastrointestinal atonic and hypomotility disorders NEC</i>		
Constipation	1	0
<i>Gastrointestinal signs and symptoms NEC</i>		
Abdominal discomfort	8	0
Dysphagia	5	0
<i>Gingival disorders, signs and symptoms NEC</i>		
Gingival pain	1	0
<i>Nausea and vomiting symptoms</i>		
Nausea	644	0
Retching	4	0
Vomiting	383	0
Vomiting projectile	1	0
<i>Oral dryness and saliva altered</i>		
Dry mouth	1	0
Salivary hypersecretion	3	0
<i>Oral soft tissue signs and symptoms</i>		
Hypoaesthesia oral	1	0
Lip pain	1	0
<i>Oral soft tissue swelling and oedema</i>		
Lip swelling	5	0
<i>Stomatitis and ulceration</i>		
Mouth ulceration	1	0
<i>Tongue signs and symptoms</i>		
Swollen tongue	2	0
<b>Gastrointestinal disorders SOC TOTAL</b>	<b>1276</b>	<b>0</b>

# Case Series Drug Analysis Print

Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>General disorders</b>		
<i>Adverse effect absent</i>		
No adverse event	1	0
<i>Asthenic conditions</i>		
Asthenia	44	0
Fatigue	87	0
Malaise	428	0
Sluggishness	1	0
<i>Death and sudden death</i>		
Sudden death	1	1
<i>Febrile disorders</i>		
Hyperpyrexia	1	0
Pyrexia	271	0
<i>Feelings and sensations NEC</i>		
Chills	45	0
Feeling abnormal	9	0
Feeling cold	36	0
Feeling drunk	1	0
Feeling hot	125	0
Feeling of body temperature change	23	0
<i>Gait disturbances</i>		
Gait disturbance	6	0
<i>General signs and symptoms NEC</i>		
Condition aggravated	2	0
Crepitations	1	0
Crying	29	0
High-pitched crying	1	0
Illness	30	0
Influenza like illness	24	0
Local reaction	209	0
Peripheral swelling	369	0
Screaming	11	0
Swelling	84	0
Swelling face	7	0
<i>Inflammations</i>		
Inflammation	53	0
<i>Injection site reactions</i>		
Injection site erythema	5	0
Injection site haemorrhage	1	0
Injection site inflammation	125	0
Injection site mass	4	0
Injection site pain	33	0
Injection site rash	21	0
Injection site reaction	187	0
Injection site swelling	3	0
<i>Oedema NEC</i>		
Face oedema	1	0
Generalised oedema	1	0
Localised oedema	1	0
Oedema	1	0
Oedema peripheral	10	0
<i>Pain and discomfort NEC</i>		
Axillary pain	1	0
Chest discomfort	22	0



# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>General disorders</b> General disorders cont'd		
Chest pain	18	0
Discomfort	6	0
Pain	47	0
Tenderness	12	0
<b><i>Therapeutic and nontherapeutic responses</i></b>		
Drug ineffective	1	0
Vaccination failure	20	0
<b><i>Vaccination site reactions</i></b>		
Vaccination site pain	4	0
<b>General disorders SOC TOTAL</b>	<b>2423</b>	<b>1</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

<b>Reaction Name</b>	<b>Total</b>	<b>Fatal</b>
<b>Immune system disorders</b>		
<i>Allergic conditions NEC</i>		
Hypersensitivity	11	0
<i>Allergies to foods, food additives, drugs and other chemicals</i>		
Reaction to excipient	1	0
<i>Anaphylactic and anaphylactoid responses</i>		
Anaphylactic reaction	18	0
Anaphylactic shock	4	0
Anaphylactoid reaction	2	0
<b>Immune system disorders SOC TOTAL</b>	<b>36</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Infections</b>		
<i><b>Bacterial infections NEC</b></i>		
Bacterial infection	1	0
Cellulitis	5	0
Injection site cellulitis	1	0
<i><b>Bordetella infections</b></i>		
Pertussis	1	0
<i><b>Central nervous system and spinal infections</b></i>		
Meningitis	2	1
<i><b>Ear infections</b></i>		
Ear infection	2	0
<i><b>Eye and eyelid infections</b></i>		
Hordeolum	1	0
<i><b>Herpes viral infections</b></i>		
Oral herpes	1	0
Varicella	1	0
<i><b>Infections NEC</b></i>		
Infection	3	0
Injection site abscess	2	0
Localised infection	1	0
Vaccination site abscess	2	0
<i><b>Lower respiratory tract and lung infections</b></i>		
Lower respiratory tract infection	1	0
<i><b>Neisseria infections</b></i>		
Meningitis meningococcal	8	0
Meningococcal infection	10	0
Meningococcal sepsis	2	0
<i><b>Sepsis, bacteraemia, viraemia and fungaemia NEC</b></i>		
Sepsis	1	0
<i><b>Skin structures and soft tissue infections</b></i>		
Rash pustular	1	0
<i><b>Streptococcal infections</b></i>		
Pneumococcal infection	2	0
<i><b>Tuberculous infections</b></i>		
Erythema induratum	11	0
<i><b>Upper respiratory tract infections</b></i>		
Nasopharyngitis	27	0
Pharyngitis	3	0
Tonsillitis	2	0
Upper respiratory tract infection	1	0
<i><b>Viral infections NEC</b></i>		
Viral infection	1	0
<b>Infections SOC TOTAL</b>	<b>93</b>	<b>1</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Injuries</b>		
<i>Fractures and dislocations NEC</i>		
Joint dislocation	1	0
<i>Non-site specific injuries NEC</i>		
Fall	3	0
<i>Overdoses NEC</i>		
Overdose	2	0
<i>Product administration errors and issues</i>		
Inappropriate schedule of product administration	1	0
Wrong product administered	1	0
<i>Skin injuries NEC</i>		
Contusion	5	0
<i>Vaccination related complications</i>		
Vaccination complication	1	0
<b>Injuries SOC TOTAL</b>	<b>14</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Investigations</b>		
<i><b>Blood gas and acid base analyses</b></i>		
Oxygen saturation decreased	2	0
<i><b>Carbohydrate tolerance analyses (incl diabetes)</b></i>		
Blood glucose decreased	1	0
<i><b>Heart rate and pulse investigations</b></i>		
Heart rate decreased	12	0
Heart rate increased	16	0
Heart rate irregular	3	0
Pulse abnormal	28	0
Pulse absent	1	0
<i><b>Immunology analyses NEC</b></i>		
Tryptase increased	1	0
<i><b>Neurologic diagnostic procedures</b></i>		
Electroencephalogram abnormal	1	0
<i><b>Physical examination procedures and organ system status</b></i>		
Body temperature	10	0
Body temperature increased	36	0
Respiratory rate decreased	1	0
Respiratory rate increased	2	0
Weight decreased	1	0
<i><b>Platelet analyses</b></i>		
Platelet count decreased	1	0
<i><b>Protein analyses NEC</b></i>		
C-reactive protein increased	1	0
<i><b>Red blood cell analyses</b></i>		
Haemoglobin decreased	1	0
<i><b>Renal function analyses</b></i>		
Blood creatinine decreased	1	0
Blood urea decreased	1	0
<i><b>Vascular tests NEC (incl blood pressure)</b></i>		
Blood pressure decreased	7	0
Blood pressure increased	2	0
<b>Investigations SOC TOTAL</b>	<b>129</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Metabolic disorders</b>		
<i><b>Appetite disorders</b></i>		
Decreased appetite	13	0
Hypophagia	1	0
<i><b>Diabetes mellitus (incl subtypes)</b></i>		
Diabetes mellitus inadequate control	2	0
Type 1 diabetes mellitus	1	0
<i><b>Food malabsorption and intolerance syndromes (excl sugar intolerance)</b></i>		
Dairy intolerance	1	0
Food intolerance	1	0
<i><b>General nutritional disorders NEC</b></i>		
Feeding disorder	2	0
Food aversion	1	0
Poor feeding infant	3	0
<i><b>Hypoglycaemic conditions NEC</b></i>		
Hypoglycaemia	1	0
<b>Metabolic disorders SOC TOTAL</b>	<b>26</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Muscle &amp; tissue disorders</b>		
<i><b>Joint related disorders NEC</b></i>		
Hypermobility syndrome	1	0
<i><b>Joint related signs and symptoms</b></i>		
Arthralgia	27	0
Joint stiffness	3	0
Joint swelling	1	0
<i><b>Muscle pains</b></i>		
Myalgia	23	0
<i><b>Muscle related signs and symptoms NEC</b></i>		
Muscle disorder	2	0
Muscle spasms	4	0
Muscle twitching	52	0
<i><b>Muscle tone abnormalities</b></i>		
Floppy infant	2	0
Muscle rigidity	22	0
<i><b>Muscle weakness conditions</b></i>		
Muscular weakness	18	0
<i><b>Musculoskeletal and connective tissue conditions NEC</b></i>		
Musculoskeletal stiffness	65	0
Toe walking	1	0
<i><b>Musculoskeletal and connective tissue pain and discomfort</b></i>		
Back pain	18	0
Limb discomfort	8	0
Neck pain	31	0
Pain in extremity	270	0
<i><b>Spondyloarthropathies</b></i>		
Arthritis reactive	1	0
<i><b>Synovial disorders</b></i>		
Synovitis	1	0
<b>Muscle &amp; tissue disorders SOC TOTAL</b>	<b>550</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Neoplasms</b>		
<i>Cardiovascular neoplasms benign</i>		
Haemangioma	1	0
<i>Nervous system neoplasms unspecified malignancy NEC</i>		
Astrocytoma	1	0
<i>Skin neoplasms benign</i>		
Haemangioma of skin	1	0
<i>Skin neoplasms malignant and unspecified (excl melanoma)</i>		
Neoplasm skin	2	0
<b>Neoplasms SOC TOTAL</b>	<b>5</b>	<b>0</b>



# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Nervous system disorders</b>		
<b>Absence seizures</b>		
Petit mal epilepsy	6	0
<b>Acute polyneuropathies</b>		
Guillain-Barre syndrome	1	0
<b>Coordination and balance disturbances</b>		
Balance disorder	6	0
Coordination abnormal	1	0
Dysstasia	2	0
Hand-eye coordination impaired	1	0
<b>Cortical dysfunction NEC</b>		
Dyspraxia	1	0
<b>Disturbances in consciousness NEC</b>		
Depressed level of consciousness	2	0
Lethargy	33	0
Loss of consciousness	30	0
Somnolence	92	0
Stupor	1	0
Syncope	590	0
<b>Dyskinesias and movement disorders NEC</b>		
Dyskinesia	27	0
Hypokinesia	1	0
Psychomotor hyperactivity	1	0
<b>Dystonias</b>		
Dystonia	1	0
Opisthotonus	1	0
<b>Facial cranial nerve disorders</b>		
Facial paralysis	1	0
<b>Generalised tonic-clonic seizures</b>		
Generalised tonic-clonic seizure	13	0
<b>Headaches NEC</b>		
Headache	1091	0
<b>Hydrocephalic conditions</b>		
Hydrocephalus	1	0
<b>Increased intracranial pressure disorders</b>		
Idiopathic intracranial hypertension	1	0
<b>Mental impairment (excl dementia and memory loss)</b>		
Cognitive disorder	1	0
Disturbance in attention	3	0
<b>Migraine headaches</b>		
Migraine	4	0
Migraine with aura	1	0
<b>Muscle tone abnormal</b>		
Hypotonia	9	0
<b>Neurological signs and symptoms NEC</b>		
Dizziness	1111	0
Fontanelle bulging	1	0
Grimacing	1	0
Meningism	2	0
Neurological symptom	1	0
Presyncope	28	0
Unresponsive to stimuli	2	0
<b>Neuromuscular disorders NEC</b>		
Muscle spasticity	1	0

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Nervous system disorders</b>		
<i>Nervous system disorders cont'd</i>		
<b><i>Paraesthesias and dysaesthesias</i></b>		
Burning sensation	2	0
Hyperaesthesia	5	0
Hypoaesthesia	48	0
Paraesthesia	57	0
<b><i>Partial complex seizures</i></b>		
Focal dyscognitive seizures	1	0
<b><i>Seizures and seizure disorders NEC</i></b>		
Epilepsy	11	0
Seizure	52	0
Seizure anoxic	9	0
Status epilepticus	1	0
<b><i>Sensory abnormalities NEC</i></b>		
Dysgeusia	1	0
Sensory disturbance	1	0
<b><i>Speech and language abnormalities</i></b>		
Dysarthria	2	0
Speech disorder	2	0
<b><i>Tremor (excl congenital)</i></b>		
Tremor	45	0
<b>Nervous system disorders SOC TOTAL</b>	<b>3306</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<i>Product quality issues NEC</i>		
Product complaint	1	0
<b>null SOC TOTAL</b>	<b>1</b>	<b>0</b>

# Case Series Drug Analysis Print

Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Psychiatric disorders</b>		
<b><i>Abnormal behaviour NEC</i></b>		
Abnormal behaviour	2	0
Staring	3	0
<b><i>Anxiety symptoms</i></b>		
Agitation	4	0
Anxiety	8	0
Nervousness	24	0
Tension	1	0
<b><i>Behaviour and socialisation disturbances</i></b>		
Aggression	2	0
<b><i>Confusion and disorientation</i></b>		
Confusional state	3	0
Disorientation	7	0
<b><i>Deliria</i></b>		
Delirium	6	0
<b><i>Disturbances in initiating and maintaining sleep</i></b>		
Insomnia	2	0
<b><i>Dyssomnias</i></b>		
Poor quality sleep	1	0
<b><i>Eating disorders NEC</i></b>		
Selective eating disorder	1	0
<b><i>Emotional and mood disturbances NEC</i></b>		
Emotional distress	5	0
Emotional poverty	1	0
Irritability	13	0
Mood altered	2	0
<b><i>Fear symptoms and phobic disorders (incl social phobia)</i></b>		
Social fear	1	0
<b><i>Fluctuating mood symptoms</i></b>		
Mood swings	1	0
<b><i>Hallucinations (excl sleep-related)</i></b>		
Hallucination	6	0
<b><i>Increased physical activity levels</i></b>		
Restlessness	2	0
<b><i>Mood alterations with depressive symptoms</i></b>		
Depressed mood	2	0
Tearfulness	6	0
<b><i>Obsessive-compulsive disorders and symptoms</i></b>		
Obsessive-compulsive symptom	1	0
<b><i>Panic attacks and disorders</i></b>		
Panic attack	3	0
Panic reaction	3	0
<b><i>Pervasive developmental disorders NEC</i></b>		
Autism spectrum disorder	1	0
<b><i>Psychiatric elimination disorders</i></b>		
Enuresis	1	0
<b><i>Sleep disorders NEC</i></b>		
Sleep disorder	2	0
<b><i>Speech articulation and rhythm disturbances</i></b>		
Lack of spontaneous speech	1	0
<b><i>Tic disorders</i></b>		
Tic	1	0
<b>Psychiatric disorders SOC TOTAL</b>	<b>116</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

<b>Reaction Name</b>	<b>Total</b>	<b>Fatal</b>
<b>Renal &amp; urinary disorders</b>		
<i>Bladder and urethral symptoms</i>		
Incontinence	3	0
Urinary incontinence	7	0
<i>Glomerulonephritis and nephrotic syndrome</i>		
Glomerulonephritis membranoproliferative	1	0
Nephrotic syndrome	1	0
<i>Urinary abnormalities</i>		
Haematuria	1	0
<b>Renal &amp; urinary disorders SOC TOTAL</b>	<b>13</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

<b>Reaction Name</b>	<b>Total</b>	<b>Fatal</b>
<b>Reproductive &amp; breast disorders</b>		
<i>Reproductive tract signs and symptoms NEC</i>		
Oedema genital	1	0
<b>Reproductive &amp; breast disorders SOC TOTAL</b>	<b>1</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Respiratory disorders</b>		
<i><b>Breathing abnormalities</b></i>		
Apnoea	2	0
Dyspnoea	24	0
Hyperventilation	18	0
Hypopnoea	1	0
Respiratory arrest	1	0
Respiratory distress	1	0
<i><b>Bronchospasm and obstruction</b></i>		
Asthma	5	0
Bronchospasm	3	0
Wheezing	6	0
<i><b>Conditions associated with abnormal gas exchange</b></i>		
Cyanosis central	2	0
<i><b>Coughing and associated symptoms</b></i>		
Cough	12	0
<i><b>Laryngeal spasm, oedema and obstruction</b></i>		
Laryngospasm	1	0
Stridor	2	0
<i><b>Nasal congestion and inflammations</b></i>		
Nasal congestion	1	0
<i><b>Nasal disorders NEC</b></i>		
Epistaxis	5	0
<i><b>Paranasal sinus disorders (excl infections and neoplasms)</b></i>		
Sinus congestion	1	0
<i><b>Pharyngeal disorders (excl infections and neoplasms)</b></i>		
Pharyngeal oedema	1	0
Pharyngeal swelling	5	0
<i><b>Respiratory tract disorders NEC</b></i>		
Respiratory disorder	1	0
<i><b>Upper respiratory tract signs and symptoms</b></i>		
Choking	2	0
Dry throat	2	0
Nasal discomfort	1	0
Oropharyngeal pain	47	0
Rhinorrhoea	2	0
Throat irritation	6	0
Throat tightness	17	0
<b>Respiratory disorders SOC TOTAL</b>	<b>169</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Skin disorders</b>		
<i>Angioedemas</i>		
Angioedema	2	0
<i>Apocrine and eccrine gland disorders</i>		
Cold sweat	148	0
Hyperhidrosis	112	0
Miliaria	1	0
<i>Bullous conditions</i>		
Blister	6	0
Erythema multiforme	4	0
<i>Dermal and epidermal conditions NEC</i>		
Dry skin	1	0
Macule	2	0
Pain of skin	17	0
Skin burning sensation	1	0
Skin discolouration	10	0
Skin discomfort	1	0
Skin induration	13	0
Skin lesion	1	0
Skin reaction	9	0
<i>Dermatitis and eczema</i>		
Dermatitis allergic	2	0
Eczema	3	0
Eczema infantile	1	0
Skin irritation	2	0
<i>Erythemas</i>		
Erythema	249	0
<i>Pruritus NEC</i>		
Pruritus	38	0
<i>Purpura and related conditions</i>		
Petechiae	16	0
Purpura	9	0
<i>Rashes, eruptions and exanthems NEC</i>		
Rash	129	0
Rash erythematous	16	0
Rash macular	50	0
Rash maculo-papular	4	0
Rash papular	2	0
Rash pruritic	17	0
Rash rubelliform	1	0
Rash vesicular	2	0
<i>Skin vasculitides</i>		
Capillaritis	1	0
<i>Skin vasomotor conditions</i>		
Livedo reticularis	6	0
<i>Urticarias</i>		
Urticaria	51	0
Urticaria pigmentosa	1	0
<b>Skin disorders SOC TOTAL</b>	<b>928</b>	<b>0</b>



# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Social circumstances</b>		
<i>Disability issues</i>		
Immobile	2	0
<b>Social circumstances SOC TOTAL</b>	<b>2</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Surgical &amp; medical procedures</b>		
<i>Induced abortions</i>		
Abortion induced	1	0
<b>Surgical &amp; medical procedures SOC TOTAL</b>	<b>1</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: Menjugate FOI 21/1063

Report Run Date: 07-Oct-2021

Data Lock Date: 30-Sep-2021 18:30:04

Earliest Reaction Date: 08-Nov-1999

MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
<b>Vascular disorders</b>		
<i>Circulatory collapse and shock</i>		
Circulatory collapse	25	0
Shock	6	0
<i>Haemorrhages NEC</i>		
Haemorrhage	1	0
<i>Peripheral vascular disorders NEC</i>		
Cyanosis	25	0
Flushing	59	0
<i>Peripheral vasoconstriction, necrosis and vascular insufficiency</i>		
Peripheral coldness	14	0
Peripheral ischaemia	1	0
Vasoconstriction	2	0
<i>Site specific vascular disorders NEC</i>		
Pallor	454	0
<i>Vascular hypotensive disorders</i>		
Hypotension	10	0
<b>Vascular disorders SOC TOTAL</b>	<b>597</b>	<b>0</b>
<b>TOTAL REACTIONS FOR DRUG</b>	<b>9890</b>	<b>2</b>
<b>TOTAL REPORTS</b>	<b>4479</b>	
<b>TOTAL FATAL OUTCOME REPORTS</b>		<b>2</b>